Vidac pharma Holding Plc Press Releases - EIN Presswire - Press Release Distribution Service

Published on September 2, 2025 - 05:00 GMT

Sphene Equity Research Update Reaffirms “Buy” Rating on Vidac Pharma

Continued analyst endorsement underscores confidence in shareholder value and growth potential Vidac pharma Holding Plc (XSTU:SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ) LONDON, UNITED KINGDOM, September 2, 2025 /⁨EINPresswire.com⁩/ -- Vidac Pharma …

Distribution channels: Chemical Industry, Companies ...

Published on July 9, 2025 - 05:00 GMT

Vidac Pharma Holding Strengthens Leadership and Prepares for Accelerated Growth

Appointment of new CTO and planned stock exchange listing mark strategic steps toward the company’s next growth phase Vidac pharma Holding Plc (XSTU:SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ) LONDON, UNITED KINGDOM, July 9, 2025 /⁨EINPresswire.com⁩/ -- …

Distribution channels: Chemical Industry, Companies ...

Published on June 25, 2025 - 05:00 GMT

Vidac Pharma Receives 'Buy' Rating and Increased Valuation from Sphene Capital, Underscoring Strong Growth Prospects

Sphene Capital Cites Strong Clinical Pipeline and Unique Approach to Tumor Microenvironment Disruption Vidac Pharma Plc (XSTU:T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ) LONDON, UNITED KINGDOM, June 25, 2025 /⁨EINPresswire.com⁩/ -- Vidac Pharma Plc, a clinical …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...

Published on June 17, 2025 - 05:00 GMT

European Commission Selects Vidac Pharma’s Tuvatexib™ Project for STEP Seal under EIC Accelerator

Vidac Pharma’s Tuvatexib™ project earns STEP Seal under Horizon Europe, recognizing its innovation in treating precancerous skin lesions. Vidac Pharma PLC (XSTU:T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ) LONDON, UNITED KINGDOM, June 17, 2025 /⁨EINPresswire. …

Distribution channels: Business & Economy, Chemical Industry ...

Published on June 10, 2025 - 05:00 GMT

Vidac Pharma Announces Publication of New Peer-Reviewed Study Highlighting Breakthrough Anti-Cancer Mechanism of VDA1275

The article explores the potential of VDA1275 both as a standalone therapy and in synergistic combination with traditional chemotherapy Vidac pharma Holding Plc (XSTU:SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ) LONDON, UNITED KINGDOM, June 10, 2025 /⁨ …

Distribution channels: Business & Economy, Chemical Industry ...

Published on May 28, 2025 - 05:00 GMT

Vidac Pharma Reports Exceptional Pharmacokinetics of Almavid™ Drug Candidate in Real-World Clinical study

Revolutionary cancer treatment demonstrates potential for Almavid™ Drug Candidate application in solid tumors. Vidac pharma Holding Plc (XSTU:SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ) LONDON, UNITED KINGDOM, May 28, 2025 /⁨EINPresswire.com⁩/ -- Vidac …

Distribution channels: Business & Economy, Chemical Industry ...

Published on March 24, 2025 - 06:00 GMT

Vidac Pharma Launches “TME++” Pediatric Brain Tumor Research Consortium

Vidac Pharma has announced the formation of “TME++,” a groundbreaking research consortium dedicated to advancing treatments for pediatric brain tumors. Vidac pharma Holding Plc (XSTU:SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ) UNITED KINGDOM, March 24, …

Distribution channels: Chemical Industry, Companies ...

Published on March 4, 2025 - 06:00 GMT

Vidac Pharma Holding PLC Announces Participation in the First Pediatric Brain Tumor Research Conference In Jerusalem

Vidac Pharma Holding Plc. is pleased to announce its participation in the First Pediatric Brain Tumor Research Meeting on March 9, 2025, in Jerusalem, Israel Vidac Pharma Holding Plc. (XSTU:T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ) LONDON, UNITED KINGDOM, …

Distribution channels: Chemical Industry, Companies ...

Published on November 7, 2024 - 10:50 GMT

Vidac Pharma receives reinvestment from shareholders to drive clinical trials of its cancer drug candidates

More than 90% of owners participated in the AGM, showing solid commitment to Vidac. Vidac initiates preparation for Phase 2b study in skin cancer. Vidac pharma Holding Plc (XSTU:SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ) SITRYA, ISRAEL, November 7, …

Distribution channels: Business & Economy, Chemical Industry ...

Published on October 24, 2023 - 07:19 GMT

Vidac Pharma Ltd receives “Seal of Excellence” from the European Commission Horizon Program

Vidac Pharma Holding Plc is proud to announce that it received high appreciation for its Clinical Proposal for treatment of Non-Melanoma Skin Cancer (NMSC) Vidac pharma Holding Plc (XSTU:SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ) LONDON, ENGLAND, UNITED …

Distribution channels: Banking, Finance & Investment Industry, Chemical Industry ...

Published on October 17, 2023 - 08:14 GMT

Vidac Pharma Holding Plc announces impressive solidarity from its shareholders, employees and collaborators

Vidac Pharma received many support calls, letters and offers to help from many of its correspondents in view of the Hamas attack on civilians in Israel Vidac pharma Holding Plc (XSTU:SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ) LONDON, ENGLAND, UNITED …

Distribution channels: Banking, Finance & Investment Industry, Chemical Industry ...

Published on September 13, 2023 - 06:00 GMT

Vidac Pharma Holding Plc to hold Annual Shareholders Meeting Sept 29th, 2023

Vidac Pharma Holding Plc will present the Balance Sheet for approval and decide on giving authority to the Board to issue new shares for expected investors. Vidac pharma Holding Plc (XSTU:SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ) LONDON, UK, September …

Distribution channels: Chemical Industry, Companies ...

Published on August 30, 2023 - 06:00 GMT

Vidac Pharma announces international experts’ participation to “Toposteric” Round Table at HTID5 in Paris Oct 24-25

Vidac Pharma is happy to announce it succeeded in bringing to the HTID5 Roundtable the participation of world specialists. Vidac pharma Holding Plc (XSTU:SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ) REHOVOT, ISRAEL, August 30, 2023 /⁨EINPresswire.com⁩/ -- …

Distribution channels: Companies, Conferences & Trade Fairs ...

Published on August 21, 2023 - 08:47 GMT

Vidac Pharma announces signature of a Research Collaboration and License Agreement with Sheba Hospital in Israel

Vidac announces a Research Collaboration with Sheba Medical Center on modification of Tumor microenvironment to facilitate Immunological treatment of Tumors Vidac Pharma Holding Plc. (XSTU:SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ) LONDON, ENGLAND, UK, …

Distribution channels: Chemical Industry, Companies ...

Published on August 15, 2023 - 10:28 GMT

Vidac Pharma Holding cooperation with Centroderm GMBH for its next Clinical Trial in Actinic Keratosis

Vidac Pharma is proud to announce that its next pre-Phase 3 Clinical trial on advanced AK will be held in close collaboration with Centroderm Gmbh Vidac pharma Holding Plc (XSTU:SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ) UK, August 15, 2023 /⁨ …

Distribution channels: Companies, Healthcare & Pharmaceuticals Industry ...

Published on August 14, 2023 - 08:47 GMT

Vidac Pharma and HCS Pharma Announce cooperative agreement on pre-clinical with Vidac Solid Tumors drug candidates

Vidac Pharma and HCS Pharma Announce cooperative agreement on acceleration of pre-clinical assays for Vidac Pharma anti Solid Tumors drug candidates. Vidac Pharma Holding Plc (XSTU:SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ) REHOVOT, UNITED KINGDOM, …

Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...